Business Context and Reporting Period
This Form 8-K Current Report was filed by Optimumbank Holdings, Inc. on June 27, 2018, covering events occurring between June 22, 2018, and June 26, 2018. The filing addresses a regulatory compliance issue regarding the company's listing on The Nasdaq Stock Market and subsequent board appointments.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and listing status.
Material Changes
- Nasdaq Non-Compliance: On June 22, 2018, Nasdaq notified the Company of non-compliance with Listing Rule 5605 regarding audit committee composition. The current committee consists of only two independent directors (Moishe Gubin and Martin Z. Schmidt) following the resignation of John Clifford on March 12, 2018. Other directors are ineligible due to involvement in financial statement preparation or legal fee conflicts.
- Cure Period: Following the annual shareholder meeting on May 29, 2018, Nasdaq granted a cure period extending until September 10, 2018, to regain compliance.
- Board Appointment: On June 26, 2018, the Company appointed Heng Fai Ambrose Chan as a director of both Optimumbank Holdings, Inc. and OptimumBank. Mr. Chan meets independence requirements and is intended to serve on the audit committee to resolve the listing deficiency.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding business plans, strategies, and the outcome of contingencies, noting these are not guarantees of future performance. The primary risk identified is the potential delisting or failure to satisfy continued listing standards if the Company cannot appoint a third independent director to the audit committee by the September 10, 2018 deadline. The Company has received regulatory approval for Mr. Chan's appointment and is processing a second application for another proposed director.
Investor Verification Checklist
- Confirm the successful appointment of a third independent director to the Audit Committee by September 10, 2018.
- Verify the status of the second director application mentioned in the filing.
- Monitor Nasdaq communications for any updates on the Company's listing status post-cure period.
- Review the background and independence status of Heng Fai Ambrose Chan and any other newly appointed directors.